Friday, 7 July 2017

Sativex (THC + CBD) plus temozolomide for recurrent GBM

This was mentioned in the comments a while back (February), but I feel these findings are significant enough to have their own post.

The original press release by GW pharmaceuticals came out on February 7.

The data was also published for the 2017 ASCO conference (click here).

"Median survival in the placebo group was 369 days, and > 550 days in the CBD:THC treatment group (NS) and 1 year survival was 83% and 56% in the CBD:THC and placebo groups, respectively (p = 0.042). "  

Even with the small numbers of patients (12 patients in the Sativex + TMZ group, 9 patients in the placebo + TMZ group), the difference in survival at one year still managed to achieve statistical significance.

Sativex (nabiximols) is available in Canada and Europe. 
Posted by at
Labels: , ,

7 comments:

  1. AGM7 July 2017 at 13:59

    Thank you, Stephen. Perhaps I missed it, where does it indicate dosage and frequency?

    ReplyDelete
  2. bs19667 July 2017 at 14:04

    Check previous thread on this:
    http://btcocktails.blogspot.com/2017/02/sativex-dosage.html

    ReplyDelete
  3. Unknown8 July 2017 at 11:03

    This is great news! Thanks for posting. Gives our family confidence in what we have been doing so far. We have been using the brand Floracy (which we can buy at local dispensaries in the Bay Area). It's a high quality CBD rich cannabis extract. Can get a bit expensive over the months but so far so good...

    ReplyDelete
  4. Stephen W22 May 2018 at 08:55

    NEW THC + CBD trial for newly diagnosed GBM:

    https://clinicaltrials.gov/ct2/show/NCT03529448

    Dose starts at 5 mg CBD + THC per day and escalates up to 80 mg CBD + THC daily (divided into 3 doses) by week nine.

    The trial will be recruiting in Spain, scheduled to open in June (next month).

    ReplyDelete
  5. Paul7 August 2018 at 09:26

    I just found this study that suggests effectiveness of CBD alongside radiotherapy.

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650324/

    ReplyDelete
  6. Stephen W21 August 2018 at 11:30

    Supporting evidence for THC+CBD with temozolomide in mice.

    https://www.ncbi.nlm.nih.gov/pubmed/30125556
    Optimization Of A Preclinical Therapy Of Cannabinoids In Combination With Temozolomide Against Glioma

    I'm uploading the full study into the Brain Tumor Library now.

    ReplyDelete
  7. Stephen W10 September 2018 at 14:02

    And another study, from the same group.

    https://www.ncbi.nlm.nih.gov/pubmed/30195736
    Targeting Glioma Initiating Cells With A Combined Therapy Of Cannabinoids And Temozolomide.

    As before, I'll be uploading this to the Brain Tumor Library

    ReplyDelete

Subscribe to: Post Comments (Atom)